Human Borrelia miyamotoi Infection in North America

Area of Science:

• * Emerging infectious diseases
• * Medical entomology
• * Microbiology

Background:

• * Borrelia miyamotoi is an emerging tick-borne pathogen transmitted by ixodid ticks.
• * First discovered in Japan in 1994, it has since been reported globally, including North America, Europe, and Asia.
• * Infection is prevalent in Ixodes ticks across the United States and Canada, with human seroprevalence ranging from 1-3% in endemic areas.

Purpose of the Study:

• * To review the epidemiology, clinical manifestations, diagnosis, and treatment of Borrelia miyamotoi infection.
• * To highlight the significance of this emerging pathogen in public health.

Main Methods:

• * Literature review of Borrelia miyamotoi epidemiology, clinical features, and treatment.
• * Analysis of diagnostic methods including PCR and blood smear examination.
• * Summary of recommended preventive strategies.

Main Results:

• * Common symptoms include fever, fatigue, headache, chills, myalgia, arthralgia, and nausea.
• * Potential complications include relapsing fever and meningoencephalitis.
• * Diagnosis requires laboratory confirmation due to nonspecific clinical signs.

Conclusions:

• * Borrelia miyamotoi infection is a growing public health concern requiring accurate diagnosis and prompt treatment.
• * Antibiotics such as doxycycline, tetracycline, erythromycin, penicillin, and ceftriaxone are effective.
• * Prevention involves avoiding tick habitats, landscape management, and personal protective measures.